Massimo Leone

Dr. Massimo Leone

Department of Neurology, Neuroalgology Unit, The Foundation of the Carlo Besta Neurological Institute, IRCCS, via Celoria 11, 20133 Milano, Italy
orcid

Research Focus & Metrics

Academic Career Length

39Years (1988-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 September 2006 in European Journal of Neurology
Verified
Journal Article
Closed access
PDF file
AMArne May
Arne May
Massimo LeoneMassimo Leone
Massimo Leone
JAJ Afra
J Afra
MLM Linde
M Linde
PSP S Sándor
P S Sándor
EFEfns Task Force
Efns Task Force

8 November 2001 in New England Journal of Medicine
Verified
Journal Article
Closed access
PDF file
Massimo LeoneMassimo Leone
Massimo Leone
AFAndrea Franzini
Andrea Franzini
GBGennaro Bussone
Gennaro Bussone
Cluster headache is the most severe form of primary headache.1 Positron-emission tomography has shown activation of the homolateral posterior inferior hypothalamic gray matter during attacks of cluster headaches, a finding that is apparently specific to the condition,2,3 and voxel-based morphometric magnetic resonance imaging (MRI) has documented alteration of the same area,4 suggesting that cluster headache may be initiated in this area. We reasoned that stereotactic stimulation of this area might prevent activation and relieve intractable forms of cluster headache.

1 November 1996 in Cephalalgia
Verified
Journal Article
Closed access
Massimo LeoneMassimo Leone
Massimo Leone
DDDomenico D’Amico
Domenico D’Amico
FMF Moschiano
F Moschiano
FFF Fraschini
F Fraschini
GBG Bussone
G Bussone

11 July 2019 in New England Journal of Medicine
Verified
Journal Article
Closed access
Peter GoadsbyPeter Goadsby
Peter Goadsby
DDDavid W. Dodick
David W. Dodick
Massimo LeoneMassimo Leone
Massimo Leone
JBJennifer N. Bardos
Jennifer N. Bardos
TOTina M. Oakes
Tina M. Oakes
JMJames M. Martinez
James M. Martinez
Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache. We enrolled patients who had at least one attack every other day, at least four total attacks, and no more than eight attacks per day during a baseline assessment, as well as a history of cluster headache periods lasting at least 6 weeks, and randomly assigned them to receive galcanezumab (at a dose of 300 mg) or placebo, administered subcutaneously at baseline and at 1 month. The primary end point was the mean change from baseline in the weekly frequency of cluster headache attacks across weeks 1 through 3 after receipt of the first dose. The key secondary end point was the percentage of patients who had a reduction from baseline of at least 50% in the weekly frequency of cluster headache attacks at week 3. Safety was also assessed. Recruitment was halted before the trial reached the planned sample size of 162 because too few volunteers met the eligibility criteria. Of 106 enrolled patients, 49 were randomly assigned to receive galcanezumab and 57 to receive placebo. The mean (±SD) number of cluster headache attacks per week in the baseline period was 17.8±10.1 in the galcanezumab group and 17.3±10.1 in the placebo group. The mean reduction in the weekly frequency of cluster headache attacks across weeks 1 through 3 was 8.7 attacks in the galcanezumab group, as compared with 5.2 in the placebo group (difference, 3.5 attacks per week; 95% confidence interval, 0.2 to 6.7; P = 0.04). The percentage of patients who had a reduction of at least 50% in headache frequency at week 3 was 71% in the galcanezumab group and 53% in the placebo group. There were no substantial between-group differences in the incidence of adverse events, except that 8% of the patients in the galcanezumab group had injection-site pain. Galcanezumab administered subcutaneously at a dose of 300 mg once monthly reduced the weekly frequency of attacks of episodic cluster headache across weeks 1 through 3 after the initial injection, as compared with placebo. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02397473.).

28 March 2000 in Neurology
Verified
Journal Article
Closed access
PDF file
Massimo LeoneMassimo Leone
Massimo Leone
DDDomenico D’Amico
Domenico D’Amico
FFF. Frediani
F. Frediani
FMF. Moschiano
F. Moschiano
LGLicia Grazzi
Licia Grazzi
GBG. Bussone
G. Bussone
Article abstract The authors performed a double-blind, double-dummy study to compare the efficacy of verapamil with placebo in the prophylaxis of episodic cluster headache. After 5 days’ run-in, 15 patients received verapamil (120 mg tid) and 15 received placebo (tid) for 14 days. The authors found a significant reduction in attack frequency and abortive agents consumption in the verapamil group. Side effects were mild. These findings provide objective evidence for the effectiveness of verapamil in episodic cluster headache prophylaxis.

10 February 2004 in Neurology
Verified
Journal Article
Closed access
PDF file
TST. Sprenger
T. Sprenger
HBH. Boecker
H. Boecker
TTT. R. Tolle
T. R. Tolle
GBG. Bussone
G. Bussone
AMA. May
A. May
Massimo LeoneMassimo Leone
Massimo Leone
A man (aged 30 years, right-handed, no medication) with a 2-year history of chronic cluster headache …